Cervical Cancer Screening: 25 to 65 Years of Age

Some types of human papillomavirus (HPV), the most common sexually transmitted viral infection, are high risk and can cause cervical cancer. Screening options for the prevention and early detection of cervical cancer depend on the age of the individual and may include cytology, cotesting, and primary high-risk HPV (hrHPV) testing. For individuals 30 to 65 years of age with a cervix, any of the three screening options is appropriate.

Refer to ARUP Laboratories’ test offerings below.

ARUP Laboratory Tests

HPV Primary Screen by PCR With Reflex to Cytology 3016636

Method

Qualitative Polymerase Chain Reaction (PCR)

Human Papillomavirus (HPV) High Risk Screen by Transcription-Mediated Amplification (TMA), with Reflex to Genotypes 16 and 18/45, ThinPrep 3016945

Method

Qualitative Nucleic Acid Amplification (NAA)

Human Papillomavirus (HPV) High Risk Screen, by Transcription-Mediated Amplification (TMA), ThinPrep 3016943

Method

Qualitative Nucleic Acid Amplification (NAA)

Human Papillomavirus (HPV), High Risk with 16 and 18 Genotype by PCR, ThinPrep 2011940

Method

Qualitative Polymerase Chain Reaction

Human Papillomavirus (HPV), High Risk with 16 and 18 Genotype by PCR, SurePath 2011933

Method

Qualitative Polymerase Chain Reaction

Having trouble viewing the algorithm? Go directly to the PDF